Nikki's financial disclosure
https://s3.documentcloud.org/documents/23926298/haley-nikki-2023.pdf
Trump's financial disclosure
Part 1
https://s3.documentcloud.org/documents/23778217/read-donald-trumps-personal-financial-disclosure-report-part-1.pdf
Part 2
https://www.documentcloud.org/documents/23778223-read-donald-trumps-personal-financial-disclosure-report-part-2
Ramaswamy Investments Seem at Odds With His Position on ‘Woke’ Culture
The billionaire biotech mogul has railed against socially conscious companies. But his financial disclosure shows he has a stake in some of the leaders in the field.
https://www.nytimes.com/2023/07/07/us/politics/vivek-ramaswamy-wealth-plane.html
"Vivek Ramaswamy, a Republican presidential candidate who made a fortune in the biotech industry, has caught the interest of primary voters with fiery critiques of the socially conscious practices of U.S. corporations, which he laid out in a book, “Woke, Inc.: Inside Corporate America’s Social Justice Scam.”
But Mr. Ramaswamy himself owns valuable investments in many companies that have embraced environmental, social and governance principles, known as E.S.G. — the kinds of “woke” corporate practices he decries — according to a financial disclosure filed with the Federal Election Commission that was released on Friday.
While many of the companies in which Mr. Ramaswamy holds an interest are household names, they are also leaders in the corporate movement to address social and environmental issues.
Among the companies that Mr. Ramaswamy is invested in are Microsoft (his holdings are valued from $1 million to $5 million), Home Depot ($250,000 to $500,000), Lockheed Martin ($500,000 to $1 million) and Waste Management ($500,000 to $1 million). All adhere to various E.S.G. principles, according to reports posted on their websites."
Questionable Stock Trade Patterns in Ramaswamy's Wall Street Past| Opinion
Sep 24, 2023 at 5:31 PM EDT
https://www.newsweek.com/we-have-some-questions-vivek-ramaswamy-about-how-he-made-his-millions-opinion-1829438
With Vivek Ramaswamy rising fast in the 2024 presidential primary polls, his pre-politics career as a biotech entrepreneur has faced growing scrutiny over allegations of pump and dump tactics. But one crucial part of his past has so far been overlooked: his short but extremely lucrative stint on Wall Street as a hedge fund investor.
Our team carefully mined the Securities and Exchange Commission's filings archives and Ramaswamy's own prior statements to recreate and analyze some of his investment history on Wall Street. What we found was shocking.
While he was at Yale Law School, Ramaswamy also worked for a hedge fund, QVT Financial. In the span of one year, Ramaswamy and his company invested in three companies—Pharmasset, Inhibitex, and Anadys, all firms in the highly esoteric field of hepatitis C treatments within biotech. And they were all acquired in major takeovers, with Ramaswamy fortuitously buying in or dramatically upping QVT's stake right around the time secret acquisition talks began in every case.
Ramaswamy's investments achieved massive returns—close to 5,000 percent by some measures, generating millions of dollars for QVT Financial; Ramaswamy's annual income also jumped during this period, from modest five and six figure salaries to more than $2.2 million in 2011 and $1.9 million in 2012, according to his own tax returns. And these were not tiny bets: In each of these three cases, at some point during the time the stock was held, Ramaswamy/QVT was either the single largest investor in the stock, or the stock was Ramaswamy/QVT's single largest position in the portfolio. Not even John D. Rockefeller, Elon Musk, Peter Thiel, Steve Schwarzman, or Warren Buffett have had such whopping returns.
(cont'd)
Was it dumb luck? We don't have evidence of insider trading. But certainly, Ramaswamy's timing could not have been better in each of these cases. And while QVT held hundreds of positions at each of these times, each of these three bets were either Ramaswamy's largest position at the time or Ramaswamy was the single largest shareholder in the stock, making their extravagant success noteworthy.
(cont'd)
Did Ramaswamy merely ride the wave of hepatitis C speculative mania taking place at the time? It would be hard for that to explain away his suspiciously good timing. Certainly, the six biotech peers and experts on securities law and corporate governance with whom we shared our findings all found Ramaswamy's lucky timing improbable.
Ramaswamy's success "looks less like lucky investing and more like a known playbook he was reading from," noted biotech investor and former Theranos whistleblower Tyler Shultz told us. "It certainly raises eyebrows given the repeated pattern." Bill George, the former CEO of Medtronic, agreed, telling us these findings showed Ramaswamy to be "a classic pump-and-dump guy who has not achieved on his own."
>Ramaswamy's success "looks less like lucky investing and more like a known playbook he was reading from
>It certainly raises eyebrows given the repeated pattern.
"Several experts on corporate law and accounting were just as stunned. "I am perplexed that the SEC has not investigated these transactions with respect to insider trading," Norman Bartczak, a financial accounting professor at Columbia Business School and adjunct professor at Columbia Law School, said. Meanwhile, Howard Shecter, the legendary corporate attorney, senior M&A counsel at Holland & Knight, and former managing partner of Morgan, Lewis & Bockius, said that Ramaswamy's trades are "evocative of SAC [Steve Cohen's hedge fund] and other notorious traders on inside information."
As renowned corporate governance pioneer, former President of ISS, and Vice Chair of ValueEdge Advisors Nell Minow put it, "Ramaswamy's partners, investors, and government regulators should have asked some hard questions about these transactions, which seem, as the British say, too clever by half. Now, he should get those hard questions from the journalists who cover Presidential politics, his opponents in the race for the nomination, and most definitely, from the voters."
More at link: https://www.newsweek.com/we-have-some-questions-vivek-ramaswamy-about-how-he-made-his-millions-opinion-1829438
>"Several experts on corporate law and accounting were just as stunned. "I am perplexed that the SEC has not investigated these transactions with respect to insider trading
IT'S TIME FOR YOU TO PUMP AND DUMP YOUR CAMPAIGN, FRAUD!
R A W S A L E R T S
@rawsalerts
🚨#BREAKING: Federal judge orders more than 150 names linked to Jeffrey Epstein unsealed, three will remain sealed
8:43 AM · Dec 21, 2023
https://twitter.com/rawsalerts/status/1737831260695785869